# An Open-label, Multidose Dose-escalation Study to Understand the Safety of CRISPR Gene-editing Therapy and Its Long-Lasting Effects in DMD Patients (MUSCLE)

> **NCT06594094** · EARLY_PHASE1 · COMPLETED · sponsor: **HuidaGene Therapeutics Co., Ltd.** · enrollment: 4 (actual)

## Conditions studied

- Duchenne Muscular Dystrophin (DMD)

## Interventions

- **GENETIC:** HG302

## Key facts

- **NCT ID:** NCT06594094
- **Lead sponsor:** HuidaGene Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-06
- **Primary completion:** 2025-12-02
- **Final completion:** 2025-12-02
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06594094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06594094, "An Open-label, Multidose Dose-escalation Study to Understand the Safety of CRISPR Gene-editing Therapy and Its Long-Lasting Effects in DMD Patients (MUSCLE)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06594094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*